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Artemisinin (ART) is a sesquiterpene lactone with an endo-peroxide bridge that is thought to be responsible for its antimalarial 
activity. It has low oral bioavailability because of aqueous insolubility, which leads to local toxicity at the site of aggregation. The 
present work focused on increasing its solubility and evaluating its permeation across a model membrane to mimic transdermal 
delivery that bypasses the hepatic metabolism. For this purpose, physical mixtures (PM), solid dispersions (SD) and lyophilized 
dispersions (LD) with different drug-polymer ratios (1:0.5, 1:1, 1:2, 1:4 and 1:9) were prepared using the hydrophilic polymer 
polyvinylpyrrolidone (PVP). Drug-polymer dispersions were characterized using X-ray diffraction (XRD) and Fourier transform 
infrared spectroscopy (FTIR). Solubility was measured in three solvents: de-ionized water, phosphate buffered saline (PBS) and 
methanol. The toluene-water partition coefficient was evaluated and compared with the literature and calculated logP values. In 
vitro diffusion of ART was studied across a polydimethylsiloxane membrane from a saturated solution of drug-polymer disper-
sions. XRD patterns showed a gradual decrease in crystallinity of ART with increasing polymer concentration, while FTIR con-
firmed no interactions between ART and PVP. Solubility was increased up to 4-, 5- and 8-fold for LD in water, PBS and methanol, 
respectively. The logP for toluene-water was 2.65 ± 0.3, which is in good agreement with literature and calculated logP values. 
Permeation was enhanced, which is attributed to the decrease in crystallinity and increase in wettability of the drug. The ART flux 
was significantly higher than that of pure ART (0.12 ± 0.01) with increasing PVP concentration for SD and LD formulations. In 
conclusion, drug-polymer dispersions with PVP improve the pharmaceutical properties of ART in the order LD>SD>PM. 
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Resistance to conventional antimalarial drugs has led to 
changes in malaria control policies globally in favor of ar-
temisinin (ART). ART is a parent compound of a novel 
family of antimalarials extracted from the Chinese tradi-
tional plant, Artemisia annua L. Asteraceae. It has been 
reported that ART is very effective against malaria parasites, 
including the multidrug-resistant falciparum species [1,2]. It 
was first isolated and characterized as an active compound 
by Chinese scientists and since then has been successfully 
utilized as an antimalarial drug [3]. ART is a sesquiterpene 
lactone with an inner peroxide bridge that is responsible for 
its antimalarial activity, as shown in Figure 1 (taken from 
CDS, Daresbury UK through freely available ACD soft-
ware). ART is a poorly water-soluble drug with an oc-
tanol-water partition coefficient (logP) greater than 2 and a 
short half-life of 2–3 h and it is extensively metabolized by 
the liver. Thus, oral bioavailability is low (32%) [1,4,5]. 
Although ART has shown excellent permeability across the  
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Figure 1  Structure of artemisinin (Chemical Database Service, Daresbury, 
UK). 
intestinal mucosa, it has low bioavailability because of poor 
aqueous solubility, which may lead to incomplete clearance 
of the malaria parasite, resulting in recurrence of malarial 
symptoms [6].  
Transdermal drug delivery facilitates the passage of 
therapeutic quantities of drug substances through the skin 
into the general circulation where they can have systemic 
effects, thus bypassing the hepatic first-pass effect. Drug 
delivery through the cutaneous route has several advantages 
over other routes but faces a major problem presented by 
the barrier function of the skin, in which the stratum corneum 
plays a vital role [7]. Physical and chemical methods are 
widely used to overcome this passive barrier. The physical 
enhancement techniques currently in use, for example ion-
tophoresis and sonophoresis, require complex equipment [8]. 
Alternatively, chemical permeation enhancers are exten-
sively used, which temporarily lower the impermeability of 
skin and facilitate the absorption of drug through the skin. 
The physical and chemical properties should be kept in 
mind whilst selecting a chemical permeation enhancer [9]. 
By far the most common penetration enhancers in use are 
ethanol, alcohols with long carbon chains, cyclic monoter-
penes, surfactants, pyrrolidones, propylene glycol, isopropyl 
myristate and dimethyl sulfoxide [10–12].   
Various techniques have been used previously to im-
prove the solubility and in turn the dissolution of drugs that 
are poorly soluble in water. Drug-polymer complexation 
using a hydrophilic polymer is quite a popular technique 
and involves formation of solid dispersions using either 
solvent evaporation or a freeze drying method [13–15]. At-
tempts had been made to enhance the dissolution rate of 
ART by making solid dispersions with PVP K-25 and cy-
clodextrins, resulting in improved dissolution to some ex-
tent [5,16]. Polyvinylpyrrolidone (PVP) is a water-soluble 
polymeric compound composed of repeating units of 
N-vinyl pyrrolidone. PVP is well tolerated physiologically 
and has been used for increasing the solubility and oral ab-
sorption of many water insoluble drugs [17,18]. Enhance-
ment of the solubility, dissolution and permeation profile of 
a water insoluble drug using PVP K-30 has been docu-
mented [19]. To date, there have been no published reports 
on the solubility in different solvents and permeation of 
ART. In the present work, we report the effect of PVP on 
solubility and in vitro diffusion of ART across a synthetic 
membrane. The drug-polymer dispersions were also char-
acterized for their solid state properties using Fourier trans-
form infrared spectroscopy (FTIR) and X-ray diffraction 
(XRD). 
1  Materials and methods 
1.1  Chemicals 
The following chemicals were used as purchased: artemis-
inin (ART) 99.9% purity (Alchem, New Dehli, India); pol-
yvinylpyrrolidone (PVP-k30, Beijing Chemical Reagent 
Company, China); methanol HPLC grade 99%+ (Merck, 
Darmstadt, Germany); potassium dihydrogen phosphate 
(VWR, Lutterworth, Leicestershire, UK); sodium chloride 
and potassium chloride (Sigma-Aldrich, Poole, Dorset, UK); 
disodium hydrogen phosphate (Fischer Scientific Chemicals, 
Loughborough, Leicestershire, UK); vacuum grease (Dow 
Corning, Midland, MI, USA). 
1.2  Artemisinin assay 
The concentration of ART was measured by a slight modi-
fication of the method described by Zhao and Zeng [20], in 
which the ART is transformed into a UV-absorbing com-
pound through an alkali reaction, i.e. by heating the solution 
with 0.2% NaOH solution. Appropriate dilutions were pre-
pared from a standard stock solution of ART and the alkali 
reaction was carried out by adding 5 mL of 0.2% NaOH 
solution to each dilution, then heated at 50 ± 1°C for 30 min 
and allowed to cool down in a refrigerator. The absorbance 
was measured at 290 nm with a UV spectrophotometer (Ag-
ilent 2005, Germany) and a calibration curve was obtained. 
The UV assay method was validated for inter- and intra-day 
variations.   
1.3  Preparation of drug-polymer dispersions  
Table 1 displays all formulation types, along with the cor-
responding sample identification codes used in this study. 
Physical mixtures (PMs), solid dispersions (SDs) and ly-
ophilized dispersions (LDs) were prepared by different 
ART to PVP ratios (1:0.5, 1:1, 1:2, 1:4 and 1:9). Physical 
mixtures were prepared by thoroughly mixing the drug and 
polymer in a pre-cleaned and dried glass mortar & pestle for 
about 5–10 min until a homogeneous mixture was obtained. 
Solid dispersions were prepared by the solvent evaporation 
method, in which an appropriate quantity of PVP was added 
to a solution of ART (1 g) in methanol (l00 mL) by contin-
uous stirring in a pre-cleaned vessel. Methanol was evapo-
rated on a rotary evaporator and the dried mass obtained 
was finally pulverized in a pre-cleaned pestle and mortar for  
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Table 1  Formulations with their codes 
Formulation type 
Drug to polymer ratio and corresponding 
formulation code 
1:0.5 1:1 1:2 1:4 1:9 
Physical mixture (PM) F1 F2 F3 F4 F5 
Solid dispersions (SD) F6 F7 F8 F9 F10 
Lyophilized dispersions (LD) F11 F12 F13 F14 F15 
 
 
about 5 min until a homogeneous mixture was obtained and 
then refrigerated in a closed vial at 5°C until further inves-
tigation.  
For LDs, SDs were dissolved in methanol until a clear 
solution was obtained. This solution was quickly solidified 
by decreasing the temperature to 50°C by immersing the 
flask in a cold methanol bath. Upon cooling, the flask was 
attached to the vacuum adapter of the lyophilizer for subli-
mation. After the solvent was completely removed, a porous 
powder residue appeared and was kept in a refrigerator at 
5°C until further investigation.  
1.4  Characterization of dispersions 
(1) Fourier-transform infrared spectrophotometry.  FTIR 
spectra were measured on a Schimadzu, 2400s Spectrometer 
using the KBr disc method. The samples were scanned over 
the range 400–4000 cm1. 
(2) X-ray powder diffraction.  XRD for each ratio of 
PM, SD and LD was performed as described earlier using a 
Bruker D8 Discover (Germany) apparatus [21]. Measure-
ment conditions included target (Cu K), voltage (35 kV), 
and current (35 mA). A system of diverging, receiving, and 
anti-scattering slits of 1°, 1°, 0.15°, respectively, was used. 
Eva software (Evaluation Package Bruker, Germany) was 
used for data processing. Patterns were obtained using a 
scan speed of 4°/min with 2 between 5° and 50°. 
1.5  Solubility studies and toluene-water partition  
coefficient 
The solubility of pure ART and PMs, SDs and LDs was 
determined in three solvents: distilled water, phosphate 
buffered saline (PBS), and methanol. An excess quantity of 
each sample was stirred with each of the solvents for 48 h at 
a constant temperature of 37 ± 2°C. The suspensions were 
then centrifuged at 4000 r/min for 30 min and a supernatant 
aliquot was taken out by a micro-pipette and analyzed spec-
trophotometrically at 290 nm after alkali reaction to deter-
mine the concentration. The solubility was also described in 
terms of the solubility enhancement ratio (ERsol), which is 
the ratio between drug solubility with the polymer and a 
standard (pure ART in this case). 
Toluene-water partition coefficient was determined using 
the shake flask method by dissolving 0.1 mg of ART in 10 mL 
of a 50:50 toluene water mixture. The flask was agitated for 
24 h and then allowed to stand for 24 h to completely sepa-
rate the layers. The amount of drug in each layer was ana-
lyzed and the toluene-water logP was calculated. 
1.6  In vitro diffusional studies across a model membrane  
Diffusion studies of the selected permeant across silicone 
membrane were performed using Franz-type diffusion cells 
which were having a receptor phase volume of ~5 mL and a 
diffusional area of ~0.788 cm2. [22]. Sheets of silicone 
membrane were cut to appropriate circular sizes and soaked 
overnight in the receptor solution. The membrane was 
mounted between the two compartments of the diffusion 
cells and vacuum grease was used to produce a leak-proof 
seal. The receptor compartment was filled with degassed 
PBS at pH 7.4 (which is near to skin pH). To prevent evap-
oration from the donor and receptor compartment, the donor 
cell and arm was covered with parafilm. Uniform mixing of 
the receptor phase was obtained with a magnetic stirrer 
placed in the receptor compartment. The diffusion cells 
were placed on a stirring bed (Variomag, USA) immersed in 
a water bath at 37 ± 5°C to maintain a temperature of ~32°C 
at the membrane surface. After 1 h the receptor phase was 
completely removed and refilled with pre-thermostated and 
degassed PBS. The donor cell was charged with 1 mL of 
saturated solution of each ratio, with excess solute present 
to maintain saturation throughout the experiment. This en-
sures that the depletion of solute in the vehicle did not be-
come the rate-limiting step. After predetermined time inter-
vals of 5, 15, 30, 45, 60, 90, 120, and 180 min, 0.2 mL of 
sample was withdrawn using micro pipette, followed by the 
addition of same volume of pre-thermostated receptor solu-
tion to maintain the sink conditions. The samples were ana-
lyzed spectrophotometrically at 290 nm after alkali reaction 
to obtain the amount permeated through the silicon mem-
brane. Experiments were conducted in triplicate to assess 
statistically significant data. 
1.7  Statistical analysis 
All the results presented are expressed as mean ± SD (n = 3) 
except for the solubility. One-way ANOVA with P  0.05 
was performed to check the significance in the values ob-
tained and post hoc comparison was carried out using the 
Turkey multiple test, where the difference in means was 
significant. 
2  Discussion and conclusions 
The logP was measured and compared with literature and 
calculated (clogP) values (calculated using ACD labs soft-
ware, CDS Daresbury, UK). ART is a lipophilic molecule 
with a logP value of 2.65 ± 0.3. The toluene-water partition 
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coefficient obtained in this experiment was in good agree-
ment with the literature logP (octanol-water) value (2.90) 
[23] and clogP value (2.40). Tables 2–4 describe the solu-
bility of ART in the presence of different concentrations of 
PVP in the three solvent systems examined in this work. 
The enhanced effect on the solubility of ART by PVP is 
also given in terms of the solubility enhancement ratio (ERsol). 
From the data obtained, it is clear that there is significant 
enhancement of the solubility of ART by PVP. The im-
provement in solubility can be explained by two different 
factors, namely, the PVP solubilizing effect and the type of 
formulation.  
PVP has a tendency to decrease the interfacial tension 
between solute and solvent, hence increasing the wettability 
of the solute, which in turn increases the solubility of the 
test compound [24]. It is evident from the results that en-
hancement of solubility is dependent on the concentration of 
polymer. Higher polymer concentrations result in higher 
solubilities of ART. A similar effect was observed in a 
study by El-Badry and Fathy [19], which showed an increase 
in solubility of a water insoluble drug, namely meloxicam, 
with increasing PVP concentrations. The type of drug- 
polymer dispersion has been shown to have some promising 
effect on enhancement of the solubility. Comparing the 
three formulation types, SD’s and LD’s had a similar effect 
on solubility, increasing the solubility by approximately the 
same degree. The exact mechanism is unknown but it could 
be related to the solubilizing effect of the hydrophilic carrier, 
PVP in this case, and formation of eutectic mixtures [25]. 
Eutectic mixtures formed as a result of solid dispersions 
have the capability to increase the wettability of poorly wa-
ter-soluble drugs and to present a microenvironment in 
which drug can reside in crystalline, amorphous or both 
forms [25]. Overall, the increase in solubility is a result of a 
decrease in particle size during formulation, increase in 
wettability and decrease in crystallinity of ART by the  
addition of PVP [26,27]. Previous reports have shown simi-
lar results, with PVP resulting in enhanced solubility and  
Table 2  Solubility of ART from PM 
Sample 
In water  In PBS  In methanol 
Solubility (mg/mL) ERsol  Solubility (mg/mL) ERsol  Solubility (mg/mL) ERsol 
C 0.013 – 0.016 – 16.36 – 
F1 0.016 1.2 0.016 1.0 20.22 1.2 
F2 0.018 1.4 0.017 1.1 23.71 1.4 
F3 0.027 2.1 0.025 1.6 39.46 2.4 
F4 0.031 2.4 0.037 2.3 49.12 3.0 
F5 0.035 2.7 0.047 2.9 61.88 3.8 
Table 3  Solubility of ART from SD 
Sample 
In water  In PBS  In methanol 
Solubility (mg/mL) ERsol  Solubility (mg/mL) ERsol  Solubility (mg/mL) ERsol 
F6 0.035 2.7 0.046 2.8 67.65 4.0 
F7 0.048 3.7 0.048 3.0 97.25 5.8 
F8 0.059 4.5 0.052 3.3 103.70 6.2 
F9 0.063 4.8 0.054 3.4 104.80 6.3 
F10 0.064 4.9 0.059 3.7 139.53 8.4 
Table 4  Solubility of ART from LD 
Sample 
In water  In PBS  In methanol 
Solubility (mg/mL) ERsol  Solubility (mg/mL) ERsol  Solubility (mg/mL) ERsol 
F11 0.016 1.2  0.050 3.1  31.01 1.8 
F12 0.021 1.6  0.057 3.5  59.75 3.6 
F13 0.026 2.0  0.065 4.1  67.65 4.1 
F14 0.031 2.4  0.068 4.2  109.75 6.6 
F15 0.052 4.0  0.072 4.5  130.58 7.9 
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dissolution because of decreased crystallinity of water in-
soluble drugs [19,28,29].  
To confirm the effect of PVP on crystallinity of ART and 
any possible interactions, the drug-polymer dispersions 
were characterized by XRD and FTIR. Figure 2 displays the 
XRD patterns of pure ART and drug-polymer dispersions 
prepared by different methods. ART is a highly crystalline 
powder and has characteristic sharp peaks at a diffraction 
angle of 2 at 7.21°, 11.96°, 14.54°, 20.24°, 21.92°, and 
32.27°. The peak appearing at a diffraction angle of 2 at 
11.96° is most prominent. The X-ray diffraction data for 
ART-PVP dispersions showed a gradual decrease in the 
peak intensities with increasing PVP content, which sug-
gests either ART has lost its crystallinity and become 
amorphous through size reduction during formulation or the 
drug has been transported into the carrier during formula-
tion. The latter aspect was more prominent in the case of 
LD, where elevation of the base line was seen at the highest 
concentration of PVP (F15 in Figure 2). PMs showed the 
least effect of PVP on crystallinity of ART and the peak 
intensities for all PM ratios were similar to pure ART, with 
no identifiable changes observed (data not shown).  
The interaction between the drug and carrier often leads 
to peculiar changes in the FTIR profile. FTIR spectra of 
selected formulations were compared with the standard 
spectra of ART and PVP-K30, as shown in Figure 3. In the 
functional group region, a broad band was observed at 3885 
cm1 and attributed to the presence of water because of the  
 
Figure 2  XRD patterns for SD and LD. 
 
Figure 3  FTIR spectra of pure ART (A), PVP-K30 (B), F5 (C), F6 (D), 
F10 (E), F11 (F), F15 (G). 
hygroscopic nature of PVP. A band at 876 cm1 (O–O–C 
linkage), which is characteristic of ART, was observed 
without shifting. All the characteristic FTIR peaks of ART 
were visible without shifting in all formulation systems, 
suggesting an absence of significant interactions between 
PVP and ART.  
In vitro diffusion across a silicone membrane was studied 
for all formulations. The steady-state flux was determined 
from the slope of the linear portion of the cumulative 
amount of drug permeation versus time plot, as shown in 
Figure 4. Permeability and diffusion coefficients were cal-
culated by applying Fick’s laws of diffusion. The permea-
tion profile and flux enhancement ratio (ER) are summa-
rized in Table 5. The cumulative amount of drug permeated 
through the silicone membrane as a function of polymer 
ratio revealed that PVP increased the rate of permeation 
markedly for each formulation system compared to pure 
ART. In the case of SD, F10 showed a maximum amount of 
drug permeation, while a gradual increase in permeation of 
ART was observed for LD with increasing PVP concentra-
tion. Although there was no significant difference in drug 
permeation for F10 and F15, ART permeation from LD 
formulations with a low PVP fraction (F1, F2, F3 and F4) 
differed significantly from similar ratios in SD formulations. 
The lyophilization process involves simultaneous primary 
and secondary drying, which results in a porous and fluffy 
dry mixture [30]. This increases the surface area and surface 
free energy and therefore drug molecules penetrate into 
membrane faster than usual. This is the reason that the ini-
tial permeation of ART was higher in the LD system than 
SD. Physical mixtures showed the lowest permeation en-
hancement because of the crystalline nature of ART, which  
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Figure 4  Cumulative drug permeated from PMs (a); SDs (b); LDs (c). 
was confirmed by XRD. The flux values increased with 
increasing PVP concentration, suggesting that PVP en-
hanced the solubility of ART and solvent uptake in the sili-
cone membrane.  
Figure 5(a) and (b) displays the relationship between the 
flux enhancement ratio and the solubility enhancement ratio, 
which suggests that an increase in solubility with varying 
concentration of PVP also increased the flux. It has been 
reported that the concentration of enhancer in a system un-
der investigation can influence the promotion of transder-
mal drug delivery [31,32]. Thus, the amount of permeation 
enhancer present in the membrane is an important factor in 
the increase in permeation rate [33]. The saturated solutions 
of PM’s, SD’s and LD’s were provided with a sufficient ex-
cess of solute (ART) to maintain a constant donor concen-        
 
Figure 5  Comparison of ER flux (a) and ER solubility (b). 
tration throughout the course of experiment for all formula-
tion systems. When equilibrium conditions are maintained, 
the flux will be maximized when the outer layer of the 
membrane is saturated with the solute. According to Dias 
and co-workers [34], ideally all saturated solutions of the 
same permeant in any solvent system should produce an 
equal flux through a membrane, independent of solute con-
centration. Examination of the values in Table 5 reveals that 
the flux across the silicone membrane obtained here was not 
constant but increased with increasing PVP-K30 concentra-
tion. This may be due to some or all of the situations exam-
ined here being non-ideal, i.e. there may have some interac-
tion between the vehicle and membrane that increased the 
diffusion coefficient of the solute within the membrane 
[35].  
The permeability coefficients as a function of PVP con-
centration revealed its dependence on the amount of poly-
mer in the formulation. The increased permeability coeffi-
cient can be the result of two factors, namely, physico-
chemical characteristics and reduction in drug crystallinity. 
First, ART is lipophilic in nature, which creates a more fa-
vorable environment for the interaction with the silicone 
membrane, which is also lipophilic [36]. The increased sol-
ubility of ART in the internal lipophilic environment of the 
silicone membrane resulted in an enhanced permeability 
coefficient. To some extent, the crystallinity of drugs affects 
drug solubility and therefore, attenuation of drug crystalli-
zation by polymers has been used for many pharmaceutical 
applications over many years [37]. PVP has a tendency to 
hamper the re-crystallization of drugs, thus amorphous forms  
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(104 × D) (cm2/min) 
Permeability coefficient 
(104 × Kp) (cm/min) 
Enhancement ratio 
ER (J) 
C 0.12 ± 0.01 1.81 ± 0.01 65.6 ± 4.15 – 
F1 0.51 ± 0.03 1.33 ± 0.29 2.69 ± 0.13 4.3 
F2 0.64 ± 0.10 1.07 ± 0.12 3.34 ± 0.50 5.3 
F3 0.66 ± 0.03 1.08 ± 0.20 3.41 ± 0.16 5.5 
F4 0.71 ± 0.42 1.26 ± 0.41 4.24 ± 2.12 5.9 
F5 0.78 ± 0.30 1.06 ± 0.89 4.98 ± 1.51 6.5 
F6 0.70 ± 0.01 1.83 ± 0.60 3.51 ± 0.02 5.8 
F7 0.89 ± 0.01 2.11 ± 0.10 4.50 ± 0.48 7.4 
F8 1.28 ± 0.24 1.08 ± 0.56 6.43 ± 1.20 10.6 
F9 3.28 ± 0.09 0.12 ± 0.38 16.39 ± 0.49 27.3 
F10 4.72 ± 0.35 7.93 ± 0.22 23.60 ± 1.72 39.3 
F11 2.37 ± 0.05 0.98 ± 0.21 11.86 ± 0.27 
19.8 
F12 2.46 ± 0.05 2.70 ± 0.16 12.28 ± 0.29 
20.5 
F13 2.85 ± 0.01 4.22 ± 0.57 14.27 ± 0.06 
23.8 
F14 3.06 ± 0.49 3.40 ± 0.38 15.33 ± 2.49 
25.5 
F15 3.21 ± 0.07 4.46 ± 0.78 16.07 ± 0.34 
26.8 
a) Results are presented as mean ± SD (n = 3).  
of drugs show an enhanced permeability [38]. The increase 
in permeability coefficient with an increasing PVP content 
reflects a reduction in crystallinity that, in turn, improves 
the permeation of ART across the silicone membrane. XRD 
patterns confirmed a prominent decrease in crystallinity 
with increasing polymer content in the cases of SD and LD.  
In conclusion, the effect of PVP on ART solubility and in 
vitro diffusion was evaluated by making PMs, SDs and LDs 
at varying concentrations of PVP-K30. Results showed that 
there is a polymer-dependent increase in solubility and 
permeation of drug across the model membrane. Higher 
concentrations of PVP result in higher solubility and per-
meation. This enhancement was attributed to many factors, 
including a decrease in crystallinity of ART, an increase in 
solute wettability and the formation of eutectic mixtures of 
drug in the SD and LD systems. Solid state properties stud-
ied by XRD confirmed the loss of crystallinity in the cases 
of SD and LD formulation systems, while no interaction 
between ART and PVP was observed using FTIR. The in-
crease in pharmaceutical properties of ART was in the order 
of LD>SD>PM. Future work will focus on making an opti-
mized formulation for transdermal delivery.  
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